Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

KRAS mutant inhibitor QTX3544

An orally bioavailable allosteric dual ON/OFF state inhibitor of multiple oncogenic KRAS mutant forms, particularly KRAS G12V, with potential antineoplastic activity. Upon oral administration, KRAS mutant inhibitor QTX3544 selectively targets and binds to KRAS, thereby inhibiting KRAS-dependent signaling. This inhibits the growth and survival of KRAS-overexpressing and mutated tumor cells. KRAS, a member of the RAS family of oncogenes, plays an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:KRAS G12V inhibitor QTX3544
KRAS G12V-preferring multi-KRAS inhibitor QTX3544
KRAS inhibitor QTX3544
Code name:QTX 3544
QTX-3544
QTX3544
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search